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Background. The significance of and threshold values for the standardized uptake value
(SUV) in FDG PET/CT to diagnose prosthetic heart valve (PHV) endocarditis (PVE) are
unclear at present.
Methods. A literature search was performed in the PubMed and EMBASE medical
databases, comprising the following terms: (FDG OR *fluorode* OR *fluoro-de*) AND (en-
docarditis OR prosthetic heart valve OR valve replacement). Studies reporting SUVs correlated
to the diagnosis of PVE were selected for analysis.
Results. 8 studies were included, with a total of 330 PHVs assessed. SUVs for PVE varied
substantially across studies due to differences in acquisition, reconstruction, and measurement
protocols, with median SUVmax values for rejected PVE ranging from 0.5 to 4.9 and for
definite PVE ranging from 4.2 to 7.4.
Conclusion. Reported SUV values for PVE are not interchangeable between sites, and
further standardization of quantification is desirable. To this end, optimal protocols for patient
preparation, image acquisition, and reconstruction and measurement methods need to be
standardized across centers. (J Nucl Cardiol 2017)
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Abbreviations
FDG 18F-fluorodeoxyglucose
PET Positron emission tomography
CT Computed tomography
PHV Prosthetic heart valve
PVE Prosthetic heart valve endocarditis
CIED Cardiac implantable electronic device
SUV Standardized uptake value
EARL European Association of Nuclear Med-
icine Research Ltd
AC Attenuation corrected/correction
NAC Non-attenuation corrected
INTRODUCTION
In recent years, 18F-fluorodeoxyglucose positron
emission tomography with computed tomography-based
attenuation correction (FDG PET/CT) has been used
increasingly in the setting of infection detection in
general and prosthetic heart valve (PHV) endocarditis
(PVE) in particular. FDG PET/CT has been proposed as
a new criterion for the modified Duke classification1 and
has been added to the European Society of Cardiology
guidelines for the diagnosis and management of infec-
tive endocarditis.2
Most of the available studies on FDG PET/CT for
PVE focus on the visual interpretation of images to
differentiate between normal and pathological findings.
FDG PET/CT is also able to semi-quantitatively mea-
sure the amount of metabolic activity of a lesion in the
form of the standardized uptake value (SUV). This
concept is appealing since it might offer objective cut-
off values to discriminate normal from pathological
uptake levels, relying less on subjective interpretation.
However, SUV is dependent on a large number of
variables regarding acquisition and reconstruction
parameters, rendering the true applicability of the term
‘‘standardized’’ somewhat questionable.
Further standardization of the SUV has been pro-
posed in a number of ways,3,4 including the European
Association of Nuclear Medicine Research Ltd. (EARL)
accreditation.
We performed a review of the available literature to
ascertain whether a range of normal values for FDG
PET/CT for PVE could be established.
METHODS
A literature search was performed in the PubMed and
EMBASE medical databases, comprising the following terms:
(FDG OR *fluorode* OR *fluoro-de*) AND (endocarditis OR
prosthetic heart valve OR valve replacement). Search results
were screened to comply with the following predetermined
criteria:
– English language only
– No single case reports, case series acceptable
– Patient group with cardiac valve replacement
– SUV values reported as median and ranges or individual
values and compared to diagnosis.
Eligible articles were read in full by one researcher
(AMS) and their references screened for possible additional
studies which fit the criteria, but none were found.
RESULTS
Out of 154 results of our initial literature search, 8
studies were found to be eligible under the predeter-
mined criteria.1,5-11 Four studies were performed on
EARL-accredited systems.6,8,9,11 In total, 330 PHVs
were assessed. Study characteristics are described in
Table 1 and boxplot representations of the SUVmax
findings for each study are shown in Figure 1.
In the seminal publication by Saby et al,1 72
patients suspected of PVE were prospectively included.
Findings on FDG PET/CT were compared to the final
diagnosis, defined according to the modified Duke
criteria after a follow-up period of 3 months. Visual
analysis was based on hypermetabolism in prosthetic
and periprosthetic areas on both attenuation-corrected
(AC) and non-AC (NAC) images. SUVmax was mea-
sured as the average of 3 measurements from 3 volumes
of interest (VOI) of 5 mm3 at equal distances from each
other. Additionally, a 35 mm3 VOI was placed in the
right atrium blood pool in a location without significant
metabolic activity from myocardium, and target-to-
background ratio (TBR) was calculated as (SUVmax
valve/SUVmax atrial blood pool). The reported sensi-
tivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and global accuracy
for visual assessment were 73%, 80%, 85%, 67%, and
76%, respectively. By adding FDG PET/CT to the
modified Duke criteria, sensitivity increased to 97%.
Bartoletti et al5 only included patients with proven
PVE in their case series of 6 patients. They did not
describe the measurement method for the reported
values. They found a large variation in SUVmax, with
several relatively low values (median 4.2, range 3.2-
10.0). In patients with the lowest values, antibiotic
therapy had been started before FDG PET/CT with
resolution of fever and other symptoms of infection.
Rouzet et al6 included 39 patients with a total of 45
PHVs in their study on FDG PET/CT and radiolabelled
leukocyte scintigraphy in PVE. Visual analysis and SUV
measurement were performed based on the same meth-
ods as reported by Saby et al and final diagnosis was
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also based on modified Duke criteria after 3 months
follow-up. The reported sensitivity, specificity, PPV,
NPV, and global accuracy for visual assessment were
93%, 71%, 68%, 94%, and 80% respectively. SUVs for
patients classified as ‘rejected’ by the modified Duke
criteria were relatively high (median 4.9, range 3.3-6.2),
but patients with no visually discernible uptake of FDG
in the region of the prosthetic valve were excluded from
the semi-quantitative analysis. Since it is reasonable to
assume that these would have represented lower SUV-
max values, the reported SUVmax values will therefore
most likely be skewed to the higher end of the spectrum.
The study by Pizzi et al7 included both patients with
PHVs and cardiac implantable electronic devices
(CIEDs). The reported sensitivity, specificity, PPV,
and NPV for the total group were 84%, 75%, 81%,
and 78%, respectively when compared to the modified
Duke criteria at 3 months. For the purpose of this review
only the values of the patients with PHVs were included.
Visual analysis was comparable to the methods outlined
by Saby et al, but SUV analysis differed in that SUVmax
was measured at any abnormal area, and blood pool
measurement was based on the mean standardized
uptake value (SUVmean) as obtained with a 30 mm3
VOI at the thoracic descending aorta. TBR was calcu-
lated as (SUVmax prosthesis/SUVmean blood pool).
The region of interest in scans without visually
detectable uptake near the prosthetic valve was placed
around the metallic components of the valve alone,
without inclusion of the adjacent tissues and blood pool,
which most likely resulted in a lower SUVmax and may
explain the exceptionally low values found in the
‘rejected’ category (median 0.5).
Fagman et al8 included 11 patients scanned for
suspected PVE. Additionally, 19 normal controls were
added in the form of patients with prosthetic heart valves
scanned for malignancy. Visual analysis, comparable to
the methods described by Saby et al, resulted in a
sensitivity of 75% and specificity of 84%, based on
patients with definite (N = 8) or without (N = 19) PVE.
Semi-quantitative analysis was performed measuring
SUVmax in or directly adjacent to the prosthetic aortic
valve. Blood pool values were determined by measuring
SUVmax in five circular ROIs on consecutive slices in
the lumen of the descending aorta at the level of carina,
avoiding inclusion of potential uptake in the wall of the
aorta. TBR was calculated as (prosthetic valve SUV-
max/SUVmax descending aorta).
In their study, Saloma¨ki et al9 included both native
valves and PHVs suspected of endocarditis, confirming
that FDG PET/CT is less capable of diagnosing native
valve endocarditis (only 1 out of 6 cases detected). For
the purpose of this review only the data of the 16
patients with PHVs were considered. Visual analysis
was performed as described by Saby et al, resulting in a
reported sensitivity of 100% (6/6 cases) but a specificity
of only 60%. SUVmax was measured in a VOI covering
the valve or prosthesis area based on co-registered CT
images. The mean blood pool values were measured in
the ascending aorta excluding the vessel wall (mean
radioactivity in a VOI of 6.8 cm3) to calculate TBR.
Two noticeably high values (7.8 and 7.2) skewed the
overall findings in the ’rejected’ category (N = 5)
upwards (median 4.8, range 2.9-7.8), with one value
reported as being this high due to a foreign body
reaction and one due to imaging relatively early after
implantation (6 weeks).
Jime´nez-Ballve´ et al10 compared different interpre-
tation criteria in their cohort consisting of patients with
PHVs and/or CIEDs compared to the Duke pathological
criteria if tissue was available or the decision of an
endocarditis expert team after a minimum of 4 months
follow-up. Using criteria comparable to those used by
Saby et al in the whole group, visual analysis resulted in
reported sensitivity, specificity, PPV, NPV, and global
accuracy of 100%, 73%, 80%, 100%, and 87%,
Figure 1. Reported SUVs in the eligible studies as median, interquartile ranges and total ranges
unless noted otherwise. Green values were reported by EARL-accredited centers. Values reported
as median with total ranges. Values reported as median with quartile ranges.
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respectively. Again, for this review only the data in PHV
patients compared to the final diagnosis were included.
SUVmax was measured in the area under suspicion and
was compared to physiological uptake (also measured as
SUVmax) in the mediastinal blood pool, calculated by
measuring a VOI with 3 mm diameter in the ascending
aorta, and in the liver, calculated by measuring a VOI
with 3 cm diameter drawn in the right hepatic lobe
excluding any areas of inhomogeneous or focally
increased uptake. As in the study by Rouzet et al,
patients with no visually discernible uptake of FDG in
the region of the prosthetic valve were excluded from
the semi-quantitative analysis, probably skewing
reported SUVmax values to the higher end of the
spectrum.
Mathieu et al11 recently studied 51 patients with 54
PHVs with no suspicion of PVE to define normal
variants and values of FDG uptake. Indications for PET
were oncology (N = 26), suspicion of prosthetic valve
endocarditis subsequently excluded (N = 17), and his-
tory of vasculitis (N = 11). Visual analysis was
descriptive, with FDG uptake described as absent,
homogeneous, or focal in 13%, 80%, and 7% of AC
images and 44%, 50%, and 6% of NAC images,
respectively. SUV measurements were performed
according to the protocol as described by Saby et al
and Rouzet et al, resulting in a median SUVmax of 3.5
(range 2.1-8.0). In subgroup analysis, values were higher
in patients referred with a history of vasculitis (median
4.7, range 3.0-8.0) than in the other patients referred for
oncologic indications (median 3.3, range 2.1-5.7) or
rejected PVE (median 3.5, range 2.1-4.7), even though
metabolic activity in the wall of the ascending aorta did
not differ significantly between groups.
DISCUSSION
In general, the included studies show that higher
SUVs are reported for patients with PVE than those
without. However, the great variations in median values
and their ranges are a concern, and proof that reported
values cannot heedlessly be extrapolated into clinical
practice.
The numerous patient- and preparation-related vari-
ables that influence the uptake of FDG in the region of
the heart make interpreting FDG PET/CT images in the
setting of PVE a challenging task. The use of antibiotics
or corticosteroids can lead to false-negative results,
foreign body reactions may be falsely interpreted as
infection, and other confounders may influence the
interpretation as well.12 Knowing this, we cannot expect
the SUV to be the only distinguishing variable. Never-
theless, there is much to be gained by performing FDG
PET/CT in a uniform way with truly standardized SUV
measurements. As our review of the literature shows,
there is currently very little standardization of how FDG
PET/CT is performed in PVE, both regarding acquisi-
tion and reconstruction protocols as well as the
definition of the region in which the uptake is to be
quantified.
Although the different studies may have used
different criteria to define the diagnosis of PVE, this
can be argued to be a lesser concern in the context of this
article. Even if the diagnostic criteria had been perfectly
equal across the studies, the reported values would still
be incomparable due to the differences in methodology
of measurement and parameters of acquisition.
EARL-accredited reconstruction is a logical step
towards better reproducibility of reconstruction param-
eters. The SUVref method, in which camera- and
reconstruction-specific filter parameters are applied to
produce images with standardized properties for SUV
measurements4 is another option, which may have the
added benefit of being applicable to non-EARL-accred-
ited sites in retrospect.
The potential negative effect of EARL-accredited
reconstructions is its relatively high level of smoothing
of images, resulting in lower reported SUVmax mea-
surements than on images based on contemporary
reconstruction methods incorporating Time-of-Flight
and other parameters, especially in the higher ranges.
For this reason it may be desirable to add EARL-
reconstructions only for the purpose of standardized
measurements, using vendor- and camera-optimized
reconstructions for visual analysis and clinical
implementation.
To be able to reliably measure values in the region
of PHVs, it is important that the physiological glucose
metabolism (and by proxy FDG uptake) of the myocar-
dium be suppressed. Many patient preparation protocols
exist, with the optimal solution still up for debate.13
Based on our own experiences, a low carbohydrate fat-
allowed diet for 24 hours, 12-hour fast and unfraction-
ated heparin bolus pre-administration results in adequate
suppression14 and shorter fasting periods should be
avoided. Centers should strive for a protocol that
reliably yields suppression in [80% of patients.13
Recently, Giorgetti et al published their findings on
increased myocardial suppression in patients receiving
low molecular weight heparin or warfarin therapy,15 and
patients receiving such therapy likely do not need
additional unfractionated heparin bolus administration.
Regarding measurement methods, a number of
studies excluded valves with no visual abnormalities
from semi-quantitative measurement, thus introducing a
potential reporting bias in the values for normal valves
and rejected PVE. As these excluded measurements
likely had values close to blood pool values, the true
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median may be expected to be lower than reported. To
reduce potential reporting bias we would recommend
that SUV be measured and reported in all PHVs, not just
in visually abnormal ones, with the same methodology
used in all measurements. To improve ease of measure-
ment (and hence reproducibility) we suggest reporting
the SUVmax obtained from a single VOI encompassing
the entire prosthesis where possible, rather than creating
mean values from multiple SUVmax measurements in
multiple VOIs.
By creating reproducible results, recommendations
based on SUV measurements could become inter-
changeable between sites, and research data from
various hospitals could safely be pooled into a larger
dataset. The latter should be of particular interest, since
the incidence of PVE is relatively low even in special-
ized centers. To allow for truly large studies with
significant statistical power, it is inevitable to include
multiple centers, which is inappropriate without better
standardization of FDG PET/CT.
Once the process of FDG PET/CT imaging is
comparable between sites, including every step from
patient preparation to image interpretation and measure-
ment, we can begin to understand the effects of the other
variables based on reliable interpretation and measure-
ment standards.
Figure 2. Example of proposed measurement standardization in a mitral valve prosthesis. Fused
PET/CT images (upper row) and corresponding attenuation-corrected PET images (below) showing
whole-valve measurement VOI (in this case a self-expanding VOI set to include voxels C40% of
maximum) and VOI sphere in the descending aorta (lower right). Uptake in myocardium (hardly
present here) and the aortic wall are excluded.
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SUVs for PVE reported in the literature are highly
dependent on acquisition, reconstruction, and measure-
ment protocols, and further standardization is needed
before values are interchangeable between centers.
Recommendations
To improve uniformity in measurements we rec-
ommend patient preparation with a carbohydrate-
restricted diet and a prolonged fast coupled with heparin
bolus administration preceding the administration of
FDG.14 Reported measurements should be performed on
reconstructions according to the EARL accreditation,
and should include whole-valve or whole-prosthesis
measurements of the SUVmax (with VOI excluding
physiological myocardial uptake) as well as a measure-
ment of the SUVmean of the blood pool in the
descending aorta (VOI excluding vessel wall) to calcu-
late a target-to-background ratio (example in Figure 2).
VOI measurements of SUVmean in the right atrium and
the liver may be of additional value to ascertain the
optimal region for TBR calculation.
We believe the above recommendations will result in
robust and reproducible measurements which will allow
for cross-center comparability and pooling of results.
CONCLUSION
SUVs reported in the current literature on FDG
PET/CT in PVE vary according to acquisition, recon-
struction, and measurement methods, emphasizing the
need for a uniform protocol to allow for better compar-
ison of results between different centers. Although not
without drawbacks, standardized measurements on
EARL-accredited reconstructions seem a sensible and
feasible starting point.
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